TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: perioperative major adverse cardiac event
Endpoint domain: Adverse events/effects
Primary endpoint: Correct responses on the Response Inhibition task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quinolinic acid to Tryptophan ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle strength of the right arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle strength of the left arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle strength of the right leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle strength of the left leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total dolutegravir concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unbound dolutegravir fractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student evaluation of curriculum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Low cardiac output syndrome (LCOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virological response rates at weeks 48 and 96
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalized maximum voluntary contraction 1-s average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CFU/ml of oral yeasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recent consistent condom use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change from baseline in St. Mark's score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: LS mean trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LS weighted mean FEV1 0-6 hrs post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TDI focal score
Endpoint domain: Life impact
Endpoint subdomain: Dyspnea
Primary endpoint: Reduction in mMASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: serum high sensitivity C-reactive protein (hs-CRP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: length of supplemental oxygen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of high-sensitivity C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of serum amyloid A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of fibrinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mother-reported externalizing behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: problem behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: observed prosocial behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of osteophytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Width of the intervertebral foramen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in Speech Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: speech in noise perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluator-rated misophonia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dose of propofol consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean fentanyl utilisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stair pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to perform IV cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial postintervention response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MSI status classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of impending death
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Open communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Healthy grieving process
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite of cardiovascular death, non-fatal myocardial infarction, non-fatal ischemic stroke, and unstable angina requiring emergency hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to definitive deterioration in HRQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Risk of deterioration in disease-related symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Participation in activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: MBI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CSI
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Languishing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cost-effectiveness analysis (QALY lost)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cognitive gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work/school functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean UACR change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Estimated GFR change (creatinine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Estimated GFR change (cystatin C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Wound re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selection of diet based on microbiota and genetic information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent of skin lesions per total body surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: repigmentation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: NPC prevalence of any pneumococcal serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiovascular parameters (systolic and diastolic blood pressure, mean arterial pressure, pulse pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of entire studies of diagnostic quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median image quality gradings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of service delivery
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reduction in NRS (Numeric Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Access to specialized care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Skin Condition Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin Hydration Change (SCH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: de novo extreme generic pain
Endpoint domain: Adverse events/effects
Primary endpoint: severe dyspareunia
Endpoint domain: Adverse events/effects
Primary endpoint: complications requiring re-admission to hospital
Endpoint domain: Adverse events/effects
Primary endpoint: incidences of injection pain
Endpoint domain: Adverse events/effects
Primary endpoint: incidences of respiratory depression
Endpoint domain: Adverse events/effects
Primary endpoint: ADCS-ADL score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: QOL-AD score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: beta-hydroxybutyrate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UACR changes from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: quickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Women's mean EPDS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: discounted quality-adjusted life-years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: post-treatment depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CR+CRi rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective efficacy against Plasmodium infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: anti-HPV GMTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: seroconversion percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tooth color
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total blood leukocyte number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: new organ failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of new or newly enlarged T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quit rate at six months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster completing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower errors during training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: higher face validity and content validity scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: forced expiratory volume at 1 s impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Progression-Free Survival (PPS)
Endpoint domain: Mortality/survival
Primary endpoint: Risk ratio of suicide attempts
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Transient side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Pain during mouth opening exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in mouth opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased correlation between DMN and FPN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy of lasmiditan for treatment of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of lasmiditan for treatment of migraine attacks
Endpoint domain: Adverse events/effects
Primary endpoint: Mean plasma EPA + DHA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-adjusted AUC0-24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-adjusted Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in IPAQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pulmonary compliance (Crs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median reduction from baseline in focal seizure frequency/28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mean improvement from baseline in Patient-Weighted Quality of Life in Epilepsy Inventory total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 90-day transplant-free survival
Endpoint domain: Mortality/survival
Primary endpoint: 90-day cumulative incidence of death
Endpoint domain: Mortality/survival
Primary endpoint: rate of clinical events (death or liver transplant)
Endpoint domain: Mortality/survival
Primary endpoint: overall performance evaluation scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: first hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: total number of hospitalizations for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: combination of cardiovascular death or hospitalization for heart failure
Endpoint domain: Mortality/survival
Primary endpoint: distress tolerance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FLA control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AFL recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in depression (HRSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in anxiety (HRSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in infant daytime sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of urethral stenosis
Endpoint domain: Adverse events/effects
Primary endpoint: Attempts at stopping smoking
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage change in LHA on maximum Valsalva maneuver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NRS score for superficial dyspareunia
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in chronic pelvic pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Sensitivity for detecting CRC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for detecting advanced adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of FIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of ocular chlamydia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prolonged intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delta creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: biopsy-proven acute rejection rates
Endpoint domain: Adverse events/effects
Primary endpoint: ACR50 scores at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ankle brachial index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VAS scores after extubation
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Non-invasive keratograph tear break up time (NIKBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Bulbar and limbal hyperaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Urine excretion rate of unchanged drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone removal volume at day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone-free rate (SFR) at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in S. mutans count in plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma MMP‐9 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Height Velocity (HV) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Discrimination Score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain alteration patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SOL values after local anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Common mental disorders (CMD) symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pessary complications
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of non-vitamin K antagonist oral anticoagulants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of non-vitamin K antagonist oral anticoagulants
Endpoint domain: Adverse events/effects
Primary endpoint: Attention maintenance to the forward roadway
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calibration of driving skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of Aterixen compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility criteria met
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Usability/satisfaction by NPS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Supportive care resource utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain severity and duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Student listening behaviours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phonological processing (blending nonsense words in noise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening uptake at 4 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Screening uptake at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NIBUT measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSImax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Public contributor involvement in trial teams
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Training provided for public contributors
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feedback on changes made due to public contributor input
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of moderate or severe COPD exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fecal butyric acid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: complete response rate
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalization rate for hyperbilirubinemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thin ideal internalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attitudes toward spanking (ATS) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adaptation levels
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 2-year composite of all-cause death or HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Implementation of at least four PA practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of practices implemented
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feeding tolerance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first bowel movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the CDS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in CVD risk factor control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Analgesic drug consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean difference of serum AMH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: maximum load to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum displacement after 3,000 cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative sufentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Piritramide consumption at 24 h post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance of trial enrollment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status